Sanzyme Biologics Private Limited is a pioneering Indian biotechnology company headquartered in Hyderabad, India, specializing in the research, development, and large-scale manufacturing of probiotics, enzymes, and fermentation-derived bioactive ingredients. With over five decades of microbial fermentation expertise, Sanzyme Biologics serves global pharmaceutical, nutraceutical, animal health, and functional food industries through proprietary strains, regulatory-ready documentation, and contract manufacturing services.
Core Business and Offerings
Sanzyme Biologics operates across three key business verticals:
-
Probiotic Strain Development and Production:
- Bacillus coagulans SNZ 1969®: A clinically studied, shelf-stable probiotic used across dietary supplements, animal nutrition, and functional foods.
- Bacillus clausii SNZ 1971™: Acid- and bile-resistant strain used for gut health and antibiotic-associated diarrhea.
- Bacillus subtilis SNZ 1972™: Applied in both human and animal health formulations.
- Saccharomyces boulardii SNZ 1986™: Yeast-based probiotic for gastrointestinal support.
-
Enzyme Solutions:
- SANCHYM™ (Chymosin): A fermentation-derived enzyme used in the dairy industry for cheese production.
- L-asparaginase: Applied in leukemia treatments and food processing to reduce acrylamide formation.
-
Fermentation-based Nutritional Ingredients:
- Vitamin K2 (MK-7): Natural, long-chain menaquinone produced via microbial fermentation, offered as a bioavailable form for cardiovascular and bone health.
These solutions are offered under Sanzyme’s own brands and as private-label, CMO, or CRO services to clients worldwide.
Specialization and Core USP
Sanzyme Biologics’ key strengths are:
- Legacy and Expertise: Over 50 years in fermentation technology, with roots tracing back to Uni-Sankyo Ltd. (a JV with Sankyo, Japan).
- Clinically Validated Probiotic Strains: Each strain backed by genetic sequencing, stability data, toxicology reports, and published human trials.
- Export-Grade Manufacturing Infrastructure: WHO-GMP, FSSAI, ISO-certified facilities with scalable production capabilities.
- Global Regulatory Readiness: Comprehensive strain dossiers prepared for GRAS, EFSA, FSSAI, and APAC registrations.
The company also offers freeze-dried probiotic powder, capsules, and finished formulations, positioning itself as a full-service contract manufacturer and R&D partner.
Financial Performance
Sanzyme Biologics operates as a high-growth biotechnology SME in India. Though exact figures are not publicly disclosed:
- The company exports to over 30 countries, contributing to 70–75% of total revenues.
- Estimated annual turnover is in the range of $10–15 million, based on export volumes and CMO business scale.
- It has seen compound annual growth rate (CAGR) of 20%+ in probiotics exports over the past five years, especially in North America, LATAM, and Southeast Asia.
- The flagship strain Bacillus coagulans SNZ 1969® accounts for a significant share of global private-label sales.
Shipment Records
Based on data from global trade and nutraceutical shipment intelligence platforms:
- Sanzyme ships bulk probiotic powders, finished capsules, and enzyme kits to the USA, Canada, Brazil, Indonesia, Philippines, Vietnam, and European markets.
- Over 200+ commercial shipments annually are recorded for probiotic strains alone.
- Major export formats include 20 kg and 50 kg HDPE drums, customized for B2B nutraceutical formulators and animal feed blenders.
- Key products shipped include SNZ 1969®, SANCHYM™, and Vitamin K2 powder in bulk form.
Target Market
Sanzyme Biologics serves global clientele including:
- Nutraceutical and dietary supplement companies
- Pharmaceutical companies seeking APIs and probiotic actives
- Functional food manufacturers
- Animal health feed formulators
- Dairy industry clients requiring chymosin and enzymes
- Private-label and contract manufacturing clients
Primary markets include North America, Latin America, Southeast Asia, the EU, and India, with increasing penetration into MENA and South Africa.
Capabilities
- WHO-GMP certified fermentation facility in Hyderabad
- Freeze-drying and spray-drying units
- In-house QC/QA and microbial R&D labs
- In-vitro and in-vivo testing capabilities
- Custom formulation development for finished product clients
- Regulatory dossier support for USA, EU, FSSAI, and other markets
Sanzyme also supports partner companies in GRAS self-affirmation and toxicological studies through its CRO network.
Certifications and Compliance
- WHO-GMP and ISO 22000:2018 Certified
- FSSAI and HALAL Certified
- Export registration with US FDA (for dietary supplements)
- GRAS self-affirmed status for Bacillus coagulans SNZ 1969®
- Kosher Certification available for key strains
- Compliance with EFSA requirements, with documentation available for registration in Europe and other regulated markets
Customer Testimonials
“SNZ 1969® has been one of the most stable probiotic strains in our product line. The technical support from Sanzyme made our regulatory process in the U.S. seamless.”
– CEO, US-based Nutraceutical Brand
“Sanzyme’s fermentation expertise and documentation quality helped us register a new enzyme formula for medical nutrition across LATAM. Reliable and compliant.”
– Regulatory Affairs Director, Pharma Company, Brazil
Major Achievements
- Developed and globally commercialized India’s first proprietary Bacillus coagulans strain (SNZ 1969®) with published clinical trials.
- Introduced SANCHYM™ as a non-animal, fermentation-derived chymosin enzyme for the cheese and dairy industry.
- Received GRAS affirmation for multiple strains used in food and dietary supplements in the U.S.
- Exhibitor at major biotech and food expos including SupplySide West, Vitafoods Europe, and CPHI India.
- Expanded manufacturing capacity by 50% in 2022 to meet growing global demand for probiotic and enzyme fermentation.
Sanzyme Biologics continues to advance the global probiotics and fermentation biotechnology landscape through science-led innovation, regulatory rigor, and customer-centric manufacturing services.
